安捷伦科技宣布,其PD-L1 IHC 28-8 PharmDx检测试剂已获得美国食品药品监督管理局的批准。此次获批扩展了该检测的伴随诊断适应症,现可用于食管鳞状细胞癌、胃癌、胃食管结合部腺癌以及食管腺癌患者。这一进展意味着临床医生能够更精准地识别可能从特定免疫疗法中获益的患者群体,为上述癌症类型的个体化治疗提供了重要的辅助诊断工具。
安捷伦科技宣布,其PD-L1 IHC 28-8 PharmDx检测试剂已获得美国食品药品监督管理局的批准。此次获批扩展了该检测的伴随诊断适应症,现可用于食管鳞状细胞癌、胃癌、胃食管结合部腺癌以及食管腺癌患者。这一进展意味着临床医生能够更精准地识别可能从特定免疫疗法中获益的患者群体,为上述癌症类型的个体化治疗提供了重要的辅助诊断工具。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.